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Abstract: Levofloxacin is the synthetic L-isomer of the racemic fluoroquinolone, ofloxacin. 
It interferes with critical processes in the bacterial cell such as DNA replication, transcription, 
repair, and recombination by inhibiting bacterial topoisomerases. Levofloxacin has broad spec-
trum activity against several causative bacterial pathogens of community-acquired pneumonia 
(CAP). Oral levofloxacin is rapidly absorbed and is bioequivalent to the intravenous formulation 
such that patients can be conveniently transitioned between these formulations when moving 
from the inpatient to the outpatient setting. Furthermore, levofloxacin demonstrates excellent 
safety, and has good tissue penetration maintaining adequate concentrations at the site of 
  infection. The efficacy and tolerability of levofloxacin 500 mg once daily for 10 days in patients 
with CAP are well established. Furthermore, a high-dose (750 mg) and short-course (5 days) 
of once-daily levofloxacin has been approved for use in the US in the treatment of CAP, acute 
bacterial sinusitis, acute pyelonephritis, and complicated urinary tract infections. The high-dose, 
short-course levofloxacin regimen maximizes its concentration-dependent antibacterial activity, 
decreases the potential for drug resistance, and has better patient compliance.
Keywords: levofloxacin, community-acquired pneumonia, pharmacodynamics, resistance, 
pharmacokinetics, clinical use
Information resources
The medical literature published in any language since 1980 on levofloxacin was 
searched using PuBMed, MEDLINE, and EMBASE. Additional citations were identi-
fied from the reference lists of published articles. Bibliographical information, includ-
ing contributory unpublished data, was also obtained from Ortho-McNeil   Janssen 
Scientific Affairs, LLC (Titusville, NJ).
Introduction
Community-acquired pneumonia (CAP) is one of the leading causes of morbidity and 
mortality in adult populations.1–4 The severity and incidence of CAP are significant, 
especially in the elderly and immunocompromised patients.5–7 CAP affects 6 million 
people in the US annually.8 Approximately 20% (1.1–1.3 million) of these patients are 
hospitalized9 with estimated cost of about US$25,000 per hospitalization10 resulting in 
over US$30 billion annual costs for hospitalizations alone; 12% of patients hospitalized 
for CAP die.9 In patients with severe CAP requiring admission to the intensive care 
unit (ICU), mortality increases to up to 30%.11–14 The most common cause of CAP is Drug, Healthcare and Patient Safety 2011:3
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Streptococcus pneumonia.15–18 Other bacterial causes include 
Haemophilus influenzae, Moraxella catarrhalis, Klebsiella 
pneumoniae, and the “atypical” CAP pathogens which include 
Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legio-
nella pneumophila.2,17,19–22 Severe CAP, generally requiring 
admission to the ICU for management, is frequently caused by 
Staphylococcus aureus and Gram-negative bacilli.13,23–25
Epidemiologic studies reveal that pathogenic organisms 
are not recovered in .50% of patients exhibiting clinical 
signs and symptoms of CAP. Thus, microbiological informa-
tion is frequently unavailable to refine initial empiric antibi-
otic treatment of CAP in either hospitalized and outpatient 
settings.9,23,25 The guidelines from the Infectious Diseases 
Society of America/Ameri  can Thoracic Society recommend 
initial empiric therapy with a respiratory fluoroquinolone 
(eg, levofloxacin 750 mg, moxifloxacin, or gemifloxicin) or 
a β-lactam plus a macrolide. In adults, fluoroquinolones are 
recommended for the treatment of CAP caused by penicillin-
susceptible S. pneumoniae, penicillin-resistant S. pneumoniae, 
Legionella pneumophilia, H. influenzae, M. pneumoniae, and 
C. pneumoniae. Levofloxacin combination therapy with an 
antipseudomonal β-lactam (or aminoglycoside) should be 
considered if Pseudomonas aeruginosa infection is a likely 
cause of pneumonia.24 Antibiotic resistance in S. pneumoniae 
has been a major problem in the US and worldwide for more 
than a decade.26 Furthermore, increasing rates of antibiotic 
resistance (most notably, penicillin, cephalosporin, and 
macrolide resistance) observed in bacteria that commonly 
cause CAP have resulted in increased treatment failures and 
inferior clinical outcomes for many patients with CAP.14,15,27–30 
Although there are reports of the emergence of resistance 
to some fluoroquinolones among S. pneumonia,26 the inci-
dence of levofloxacin-resistant organisms has remained 
steady with resistance rates of ,1% worldwide.31–35
Levofloxacin (Figure 1) is a light yellowish-white 
crystal or crystalline powder with a molecular weight of 
370.38 g/mol. It interferes with critical processes in the 
bacterial cell, such as DNA replication, transcription, repair, 
and recombination, by inhibiting bacterial topoisomerases. 
Human cells lack these topoisomerases, which are essential 
for bacterial DNA replication, providing specificity against 
bacterial DNA topoisomerases that are responsible for 
separating the strands of duplex bacterial DNA, inserting 
another strand of DNA through the break, and then resealing 
the originally separated strands.36,37 Levofloxacin is active 
against a broad range of Gram-positive, Gram-negative, and 
cell-wall-  deficient (atypical) bacteria that may be causative 
pathogens in   community-acquired and nosocomial   infections. 
  Levofloxacin is a well-established treatment option for 
respiratory and urinary tract infections (UTI), particularly 
since levofloxacin is active against some penicillin – and 
macrolide-resistant species (eg, S. pneumoniae – the most 
common causative pathogen for community-acquired bacte-
rial respiratory infections).31–34,38,39 The incidence of penicil-
lin- and macrolide-resistance in many bacterial species is both 
high and widespread.40 In the US, a high-dose, short-course 
regimen of levofloxacin (750 mg once daily for 5 days) is 
approved for the treatment of adults with CAP, acute bacterial 
sinusitis (ABS), complicated UTI, and acute pyelonephritis 
(AP). The use of levofloxacin, including some data on the 
high-dose, short-course treatment regimen, has been reviewed 
previously.39 This review focuses on the pharmacology of 
levofloxacin in the treatment of CAP.
Pharmacodynamic properties
Spectrum of activity
Levofloxacin is the L-isomer of the racemic fluoroqui-
nolone ofloxacin.39,41 Topoisomerase IV is the main target 
for levofloxacin in Gram-positive bacteria and DNA gyrase 
(topoisomerase II) is the target in Gram-negative bacteria.42 
Levofloxacin has a broad spectrum of antibacterial activ-
ity that includes several Gram-positive and Gram-negative 
aerobes and cell-wall-deficient (atypical) bacteria. The 
minimum inhibitory concentrations (MIC) of levofloxacin 
required to inhibit the growth of 90% of clinical isolates 
(MIC90) are used as assessments of the in vitro activity of 
levofloxacin. The levofloxacin MIC breakpoints for S. pneu-
moniae defined by the Clinical and Laboratory Standards 
Institute are: #2 mg/L (susceptible), 4 mg/L, (interme-
diate), and $8 mg/L (resistant).41,43 Also, levofloxacin 
generally demonstrates good in vitro activity against pen-
icillin-resistant S. pneumoniae strains. S. pneumoniae with 
reduced susceptibility to penicillin commonly cause CAP. The 
levofloxacin MIC90 for penicillin-  susceptible, -i  ntermediate, Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
61
Levofloxacin in community-acquired pneumonia
and -resistant isolates of S. pneumoniae was 1 mg/L in 
  multiple studies, with .97% of isolates testing susceptible 
to the drug.31–34,38,44
Levofloxacin has variable activity against S. aureus, 
depending on methicillin susceptibility. Levofloxacin 
had MIC90 values of 0.25–4.0 mg/L against methicillin-
susceptible S. aureus isolates, whereas methicillin-resistant 
S. aureus isolates exhibited levofloxacin resistance, MIC90 
values ranging from .4 to $64 mg/L.38,44–46 The in vitro 
activity of levofloxacin against Enterococcus faecalis was 
limited (MIC90 of 8 to $32 mg/L in vancomycin-susceptible 
and -resistant strains). Although levofloxacin has limited 
activity against co  agulase-negative staphylococci (.4 mg/L, 
54.1%).45 It has demonstrated good in vitro activity against a 
range of other Gram-positive bacteria, such as   Streptococcus 
pyogenes (1 mg/L, 99.9%)32,33 and other β-hemolytic strep-
tococci (0.5–1 mg/L, 99.1%–100%).47
Generally, levofloxacin has good in vitro activity against 
Gram-negative bacteria including the common respiratory 
tract pathogens H. influenzae.31,35,38,44,48–50 Haemophilus 
parainfluenzae,50 and M. catarrhalis31,35,44,48–50 as well as 
urinary tract pathogens (K. pneumoniae,38,44,51 Enterobacter 
cloacae,38,44,51–53 and Proteus mirabilis38,45,48). The values of 
MIC90 for levofloxacin against isolates of H. influenzae, 
H. parainfluenzae, and M. catarrhalis were #0.06 mg/L 
with nearly 100% susceptibility rates. Levofloxacin was 
also highly active against β-lactamase-positive isolates of 
H. influenzae31–34,38 and M. catarrhalis,31,44,48–50,54,55 However, 
the activity of levofloxacin is variable against Escherichia 
coli and P . aeruginosa. The MIC90 of levofloxacin against 
E. coli ranged from #0.06 mg/L (susceptible) to .8 mg/L 
(resistant).38,44,45,51,56 Levofloxacin showed lower levels of 
activity against isolates of P . aeruginosa, MIC90 values 
ranging from 0.5 mg/L to 64 mg/L and susceptibility rates 
of 71%–94%.38,44,45,48,51 Levofloxacin also had limited activ-
ity against extended-spectrum β-lactamase-producing 
K.   pneumoniae (MIC90 of .8–32 mg/L).45 Levofloxacin 
has good activity against the cell-wall-deficient (atypical) 
organisms C. pneumonia.57–60 L. pneumophila,38,44,48,57,61,62, and 
M. pneumonia,48,57,63–65 MIC90 values being #2 mg/L.
Bactericidal activity
The bactericidal activity of levofloxacin is con  centration-
dependent,66 and the minimum bactericidal concentration 
(MBC) of levofloxacin was #4× the MIC against the majority 
of isolates for a number of causative pathogens of respira-
tory tract infections.59,60,64,65,67 The MBC90 of levofloxacin 
was 1–4× the MIC against the majority of M. pneumoniae 
isolates (MBC of #0.5–1.0 mg/L), as reported by multiple 
authors.59,60,63–65,67 The MBC of levofloxacin was 1–2× the 
MIC (#0.06–4 mg/L) against K. pneumoniae, P . aeruginosa, 
E. coli, and E. cloacae.51 Levofloxacin has a post-antibiotic 
effect (PAE) of 2.0–4.5 hours depending on the pathogen.39 
The PAE of levofloxacin against S. pneumoniae was up 
to 4.5 hours at 10× the MIC. Furthermore, levofloxacin 
has shown PAEs against methicillin-susceptible S. aureus 
(MSSA), K. pneumoniae, L. pneumophila, and anaerobes39 
as well as against erythromycin-resistant and -susceptible 
strains of L. pneumophila.61
Resistance
Resistance to antibacterial drugs in S. pneumoniae has been 
a major problem in the US for more than a decade.26 The 
primary cause of reduced susceptibility of bacteria (par-
ticularly S. pneumoniae) to fluoroquinolones is at least one 
mutation in the parC and parE genes that code for DNA 
topoisomerase IV or gyrA and gyrB genes that code for DNA 
gyrase.68,69 Another fluoroquinolone resistance mechanism 
involves active drug efflux through mutation in the efflux 
regulatory genes mexR and nfxB.68,70 Although there are 
reports of the emergence of fluoroquinolone resistance among 
S. pneumoniae,26 the incidence of levofloxacin-resistant organ-
isms has remained stable to date at #1% worldwide.31–35
In the worldwide PROTEKT surveillance program 
between 1999 and 2000, levofloxacin-resistant isolates of 
S. pneumoniae were identified; 94% of these isolates had 
at least one mutation in the genes coding for topoisomerase 
IV as well as in the genes coding for DNA gyrase.69 The 
SENTRY surveillance program (1997–2005) identified 
fluoroquinolone-resistant isolates of β-hemolytic Streptococ-
cus spp. as having significant mutations in the parC or gyrA 
gene, or both. Only mutations in parC were associated with 
lower MIC values.47 A report of an in vitro pharmacodynamic 
model simulating the concentration of levofloxacin in the 
epithelial lining fluid (ELF) after once daily administration 
of 500 mg revealed that all five isolates of S. pneumoniae 
containing the first-step parC mutation had levofloxacin 
resistance within 48 hours ($16-fold increase in MIC) and 
four of the isolates acquired a second-step (gyrA) mutation.71 
The acquisition of a second-step mutation appeared to be 
related with an area under the concentration–time curve 
(AUC):MIC ratio of #256; this indicates that to prevent 
levofloxacin resistance from being acquired in isolates 
with a first-step parC mutation, the AUC:MIC ratio target 
should be .256.71 When the range of free AUCs (fAUCs) of 
levofloxacin and other fluoroquinolones were simulated, the Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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results demonstrated that fAUC:MIC ratios of #82 and #86 
for levofloxacin were associated with a first-step parC muta-
tion and second-step gyrA mutation in S. pneumoniae. These 
resistance breakpoints for levofloxacin were significantly 
higher (P # 0.001) than those for other tested fluoroquinolo-
nes (gatifloxacin, gemifloxacin, and moxifloxacin) using post 
hoc analysis. Furthermore, the higher the fAUC:MIC ratio 
for each fluoroquinolone, the more delay in the development 
of first- or second-step mutations was observed.72
In the SENTRY (worldwide, 1997–2004),47 PROTEKT 
(US and Canada, 1999–2002),32–34 and TRUST (US, 
1998–2002)35 surveillance programs, the overall levofloxa-
cin resistance rate in S. pneumoniae isolates was #1%; in 
penicillin-resistant isolates, the overall rate of levofloxacin 
resistance was 0.9%–2.7%.31,34,35 In the TRUST surveillance 
program from 2001 to 2005, the rate of S. pneumoniae 
resistance to levofloxacin changed from 0% to 0.5% and the 
resistance of these isolates to penicillin resistance increased 
from 27.4% to 28.9%. Amoxicillin/clavulanic acid resistance 
increased from 6.5% to 12.9%, and clindamycin resistance 
increased from 12.1% to 18.6%.73 The levofloxacin 750 mg 
dose has been directly compared to imipenem–cilastatin 
in the treatment of nosocomial pneumonia. The average 
age of the patients was 55 years and 438 patients were 
  randomized. Forty-two percent of patients in the levofloxacin 
arm were $65 years of age. The clinical success rate in the 
intention-to-treat population was 66.2% in the levofloxacin 
arm vs 69.4% in the imipenem arm. In the clinically evalu-
able population, the success rates were 59.3% and 62.5% 
for levofloxacin and imipenem, respectively.74 Other data 
from 1998 and 2005 revealed that the levofloxacin-resistant 
isolates of H. influenzae or M. catarrhalis could not be 
identified in large worldwide surveillance studies.32–34,49,54,55 
However, surveillance studies have demonstrated resistance 
to levofloxacin in MSSA and methicillin-resistant strains of 
S. aureus (MRSA) (3.4%–10.1% and 76.6%–79.2%, respec-
tively) and P . aeruginosa (24.7%).45,46,56
Pharmacokinetics and metabolism
Levofloxacin is rapidly absorbed after oral administration 
and shows linear pharmacokinetics for both single- and 
multiple-dose (once daily) regimens. The oral solution and 
tablet formulations are bioequivalent to the intravenous for-
mulation.41 The mean pharmacokinetic parameters obtained 
in different studies of intravenous and oral levofloxacin in 
healthy adults75,76 are comparable to those reported in the 
manufacturer’s US prescribing information.41 The peak 
plasma concentration (Cmax) after single 750 mg doses of 
levofloxacin given to healthy volunteers was 11.3 mg/L75 
and 12.1 mg/L for intravenous administration, compared 
with 7.1 mg/L76 and 9.3 mg/L41 for oral administration. When 
given in multiple doses levofloxacin had Cmax of 12.1 mg/L 
and 12.4 mg/L for intravenous administration compared with 
8.6 mg/L for oral ones.41,76 Levofloxacin steady-state condi-
tions were reached within 48 hours of initiating once-daily 
intravenous or oral 750 mg.41 After oral administration, the 
Tmax of levofloxacin is reached within 1–2 hours with an 
absolute bioavailability of oral levofloxacin 500 mg and 
750 mg of approximately 99%.41,75,76 Systemic exposure to 
levofloxacin was similar for the intravenous and oral for-
mulations upon administering equal doses of levofloxacin.41 
The AUC24 was 103 mg h/L75 and 90.7 mg h/L76 at steady 
state after intravenous or oral adminis  tration of levofloxacin 
750 mg once daily, respectively.
The in vitro studies revealed that 24%–38% of levo-
floxacin was bound to plasma proteins (mainly albu-
min) and the binding was independent of levofloxacin 
  concentration.41 The volumes of distribution obtained in 
pharmacokinetic studies ranged from 74–112 L after single 
or multiple doses of levofloxacin 500 mg or 750 mg.75,76 
Levofloxacin is distributed extensively in tissues and fluids 
throughout the body and accumulates in phagocytic cells.39 
Furthermore, the mean concentrations of levofloxacin in 
tissues, ELF, alveolar macrophages, polymorphonuclear 
leukocytes, paranasal sinus mucosa, and urine, surpass the 
concentration of levofloxacin in the plasma.39,77–83 It has 
been reported that the paranasal sinuses mucosa:plasma 
concentration ratio was 2.56 at Tmax after a single 500 mg 
oral dose of levofloxacin. The concentration of levofloxacin 
in the paranasal sinuses mucosa was generally higher than 
the MIC90 of the common causative pathogens for upper 
respiratory tract infec  tions (0.008–2.0 mg/L), including 
penicillin-susceptible, -intermediate, and -resistant isolates 
of S. pneumoniae.82 In healthy volunteers, oral levofloxacin 
(500 or 750 mg) had a mean ELF:plasma concentration 
ratio at steady state of 1.16 using population pharmacoki-
netic modeling and 3.18 using Monte Carlo simulation.82 
At a lower dosage of levofloxacin (500 mg once daily for 
3 days), Cmax and AUC24 values for the drug were signifi-
cantly (P , 0.01) higher in the polymorphonuclear leuko-
cytes than in plasma.84 Reassuringly, the concentrations of 
levofloxacin in the ELF and alveolar macrophages were 
1.5- to 6-fold higher than that in the plasma at steady state 
after receiving levofloxacin 500 mg once daily for 5 days 
in older patients undergoing diagnostic bronchoscopy with 
a mean age of 62 years.80Drug, Healthcare and Patient Safety 2011:3
Table 1 Dosing in patients with diminished renal function
Renal status Initial dose Subsequent dose
CLCR $ 50 mL/min 500 mg 500 mg q24h
CLCR 20–49 mL/min 500 mg 250 mg q24h
CLCR 10–19 mL/min 500 mg 250 mg q48h
Hemodialysis 500 mg 250 mg q48h
CAPD 500 mg 250 mg q48h
CLCR $ 50 mL/min 750 mg 750 mg q24h
CLCR 20–49 mL/min 750 mg 750 mg q48h
CLCR 10–19 mL/min 750 mg 500 mg q48h
Hemodialysis 750 mg 500 mg q48h
CAPD 750 mg 500 mg q48h
Abbreviations: CLCR, creatinine clearance; CAPD, chronic ambulatory peritoneal 
dialysis; q, every.
Table 2 Levofloxacin indications and dosing for patients with 
upper respiratory tract infections and with normal renal function
Type of infection Dose Frequency Duration
Community acquired pneumonia 500 mg q24h 7–14 days
Community acquired pneumonia 750 mg q24h 5 days
Nosocomial pneumonia 750 mg q24h 7–14 days
Acute bacterial exacerbation  
of chronic bronchitis
500 mg q24h 7–14 days
Acute bacterial sinusitis 500 mg q24h 10–14 days
Acute bacterial sinusitis 750 mg q24h 5 days
Abbreviation: q, every.
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Levofloxacin is eliminated mainly through the kidneys, 
75%–87% of the dose excreted being unchanged in the 
urine within 48–72 hours of administering oral levofloxacin 
500 or 750 mg; ,4% is excreted in the feces.41,75,76 After a 
single dose of levofloxacin 750 mg, the mean drug concen-
tration in the urine was 475 mg/L at 4 hours and 186 mg/L 
at 24 hours;77 ,5% of the dose is excreted in the urine as 
inactive metabolites of levofloxacin.41 The mean total body 
clearance (CL) of levofloxacin in healthy volunteers was 
reported as 8–9.4 L/h75,76 and 8.6–13.6 L/h.41 Levofloxacin 
appears to undergo glomerular filtration as well as tubular 
secretion.41 After single or multiple doses of oral or intrave-
nous levofloxacin 750 mg, the mean terminal plasma elimi-
nation half-life (t1/2β) is 7.5–8.8 hours in pharmacokinetic 
studies.75,76 The t1/2β of levofloxacin is increased and the CL 
reduced in patients with impaired renal function (creatinine 
clearance CLCR , 50 mL/min); therefore dosage adjustment 
is required to avoid drug accumulation as shown in Table 1.41 
Furthermore, levofloxacin is not cleared effectively by hemo-
dialysis or continuous ambulatory peritoneal dialysis.39,41 
The pharmacokinetic properties of levofloxacin are not 
influenced by age, gender, or race, and they do not show 
noticeable differences between healthy adults, patients with 
HIV ,39 or patients with severe community-acquired bacterial 
infections.41 Levofloxacin pharmacokinetics in hepatically-
impaired patients have not been investigated; however, 
because of the limited hepatic metabolism of levofloxacin, 
hepatic impairment is unlikely to have a prominent effect on 
the drug pharmacokinetics.41
Clinical efficacy
The efficacy of levofloxacin 750 mg once daily (intrave-
nous and oral) for 5 days in adults with CAP,66 ABS,85 and 
complicated UTI86,87 has been assessed in several random-
ized, double-blind, multicenter, noninferiority trials.66,85–87 
The endpoints were the clinical success rate (proportion of 
patients showing either a clinical cure or improvement with 
no need for further antimicrobial therapies in both situations) 
1–2 weeks after the end of treatment,66 or at 2–3 weeks of the 
study,85 or the microbiological eradication rate (all pathogens 
identified in samples at the study entry were eradicated) at 
2–3 weeks of the study.86,87 Levofloxacin indications and 
dosing for patients with normal renal function are summa-
rized in Table 2.
Patients enrolled in the noninferiority trial with CAP 
were aged $18 years and were diagnosed with mild-to-
severe CAP. Other inclu  sion criteria involved one or more 
signs or symptoms including fever, a white blood cell count 
of .10,000 cells/mm3, or hypothermia. The exclusion cri-
teria included the following conditions: patients without 
a confirmed diagnosis of CAP, patients who did not come 
to the follow-up visit, patients who increased (.120%) or 
reduced (,80%) the scheduled doses, and patients who 
had additional antimicrobial therapy during treatment with 
levofloxacin.66 Patients with mild-to-severe CAP received 
750 mg levofloxacin (intravenous or oral) once daily for 
5 days or 500 mg once daily for 10 days. Subjects receiv-
ing the higher dosage of levofloxacin were given a placebo 
for the last 5 days of the 10-day treatment regimen.66 
  Levofloxacin susceptibility testing of the causative patho-
gens was performed, but initial treatment was empirical. The 
noninferiority criteria were established as the upper limit 
of the 2-sided 95% CI for the between-group difference in 
the clinical success rate ,15%, if both treatment groups 
had a clinical success rate of 80%–90%, or ,10%, if both 
treatment groups had a clinical success rate of $90%.66 
The results revealed that levofloxacin 750 mg once daily for 
5 days was noninferior to 500 mg once daily for 10 days in 
the treatment of mild-to-severe CAP in the overall patient 
population,66 as well as for patients with CAP caused by 
atypical organisms (C.   pneumoniae or M. pneumoniae),88 
and for elderly patients aged $65 years.89Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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In patients receiving either the levofloxacin 750 mg or 
500 mg regimen, baseline characteristics were similar and 
overall microbiological eradication rates were similar in 
both groups.66 The eradication rates for both the 750 mg 
and 500 mg regimens were high for subgroups of micro-
biologically evaluable patients infected with aerobic Gram-
positive (82.8% vs 85.3%) and Gram-negative (96.2% vs 
90.7%) pathogens, as well as other pathogens (93.8% vs 
96.2%). Eradication rates for S. pneumoniae, H. influenzae, 
and H. parainfluenzae in the corresponding post-therapy 
visit were 86.4% vs 85%, 92.3% vs 85.7% and 100% vs 
90%, respectively.66 Retrospective analysis revealed that 
the clinical success rates in patients with CAP caused by 
H. influenzae, H. parainfluenzae, or S. pneumoniae were 
also similar between the levofloxacin 750 mg and 500 mg 
treatment groups (92.3% vs 92.9%, 100% vs 90%, and 90.9% 
vs 90%, respectively).66
The efficacy of the high-dose, short-course of levo-
floxacin in achieving early resolution of symp  toms has been 
studied.90 Resolution of purulent sputum, shortness of breath, 
chills and cough were 40.6% vs 30.7%, 35.1% vs 27.7%, 
54.8% vs 54.2%, and 10% vs 10.1% comparing patients who 
received the levoflox  acin 750 mg or 500 mg regimen, respec-
tively. Furthermore, 99.4% of the 158 pathogens isolated at 
study entry were susceptible to levofloxacin and there was 
no significant difference between treatment groups in the 
time of switching from the intravenous administration of 
levofloxacin to oral administration of the drug.90 High-dose, 
short-course of levofloxacin (750 mg once daily for 5 days) 
also had good efficacy in the subgroup of patients with severe 
CAP, demonstrating high clinical success rates of .85%. 
Overall, high microbiological response rates ($87.5%) were 
observed in the subgroup of microbiologically evaluable 
patients receiving levofloxacin regardless of the treatment 
regimen.91 In the same study, microbiological eradication 
was observed in 88.2% of typical pathogens identified from 
respiratory cultures and 90% of atypical pathogens.91
It has been reported that levofloxacin 750 mg once daily 
for 5 days has good efficacy in patients with CAP caused 
by atypical organisms.88 The overall clinical success rate 
of levofloxacin 1–2 weeks after treating CAP caused by 
a single atypical path  ogen, was .95%. Noninferiority of 
levofloxacin 750 mg once daily for 5 days compared with the 
10-day regimen was also established in this study. The overall 
clinical success rate of the levofloxacin 750 mg regimen was 
94.8% for CAP caused by atypical pathogens, compared with 
96.5% for the levofloxacin 500 mg regimen.88 Furthermore, 
the clinical success rates at the 1–2 weeks post-treatment 
visit for patients with C. pneumoniae, L. pneumophila, 
and M. pneumoniae were comparable between the groups 
receiving the levofloxacin 750 mg and 500 mg dosing regi-
men (90.9% vs 100%, 100% vs 100%, and 95.3% vs 94.4%, 
respectively).88
Post-marketing surveillance
Post-marketing data demonstrated that levofloxacin simul-
taneous administered with warfarin may increase the pro-
thrombin time. Therefore, coagulation studies and bleeding 
should be monitored in patients receiving the two drugs 
  concomitantly.41 Levofloxacin does not currently have a 
US Food and Drug Administration approved indication 
in patients aged ,18 years. Like other fluoroquinolones, 
levofloxacin decreases theophylline metabolism and dosage 
adjustment for theophylline may be required for concurrent 
administration of both drugs. Concomitant fluoroquinolone 
administration with cyclosporin resulted in elevated serum 
concentrations of ciclosporin, but these alterations were 
not clinically significant.41
Safety and tolerability
Intravenous levofloxacin must be administered slowly as an 
infusion over a minimum period of 60–90 minutes, depending 
on the dose. Levofloxacin tablets or oral solution are gener-
ally prescribed at dosages of 250, 500, or 750 mg once daily. 
The tablet formulation of levofloxacin can be taken with or 
without food; however, the oral solution should be taken 
1 hour prior to or 2 hours after meals. In patients receiving 
levofloxacin, sufficient hydration should be maintained to 
prevent excessively concentrated urine. Levofloxacin should 
be administered at least 2 hours apart from some agents such 
as magnesium- or aluminium-containing antacids, sucralfate, 
metal cations, zinc-containing multivitamins, or didanosine.
Data from patients aged $65 years (phase III clinical 
  trials) demonstrated no differ  ence between elderly and younger 
patients for safety or effectiveness of levofloxacin. Elderly 
patients may be more sensitive to levofloxacin, mainly due to the 
effect of the drug on the QT interval. Thus, caution is required in 
the simultaneous administration of levofloxacin with drugs that 
prolong the QT interval such as class IA or class III antiarrhyth-
mics. Although, levofloxacin is a very safe fluoroquinolone, 
caution and a risk/benefit assessment is required with the use 
of levofloxacin in the elderly due to the increased risk of severe 
tendon disorders in this group of patients,   particularly if they 
are receiving corticosteroids.41 However, it should be stated that 
there is no evidence that tendon rupture is more likely to occur 
with levofloxacin than with any other fluoroquinolone.92 Blood Drug, Healthcare and Patient Safety 2011:3 submit your manuscript | www.dovepress.com
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glucose monitoring is recommended in patients with diabetes 
mellitus receiving simultaneous hypoglycemic agents and/or 
insulin, because symptomatic hyperglycemia and hypoglyce-
mia have been reported with levofloxacin administration.41 
Concomitant administration of fluoroquinolones (including 
levofloxacin) with NSAIDs may increase the risk of central 
nervous system stimulation and convulsive seizures.41
Levofloxacin 750 mg once daily for 5 days is a well-
tolerated fluoroquinolone for patients with CAP or UTI.86,87,93 
In a pooled analysis of patients with respiratory infections 
receiving the levofloxacin 750 mg regimen or 500 mg regi-
men, the results revealed that 4.5% and 4.9% of patients, 
respectively, had adverse effects during the therapy. The 
adverse effects in both dosage regimens included nausea, 
vomiting, diarrhea, dyspepsia, constipation, abdominal 
pain, headache, insomnia, and dizziness. The incidence of 
levofloxacin-associated adverse effects was similar between 
both treatment regimens (8% vs 7.6%).93
The use of fluoroquinolones and exposure to the sun or 
UV light has been associated with photosensitivity   reactions.41 
Fluoroquinolones can potentially prolong the QT interval 
but there are no reported cases of torsade de pointes in any 
clinical or post-marketing trials.41,93 It has been reported 
that levofloxacin is associated with Clostridium   difficile 
diarrhea, as are most other antibacterial agents. Severity 
ranges from mild diarrhea to pseudomembranous colitis.41 
The incidence of drug-related adverse effects in patients with 
CAP or ABS was similar between the levofloxacin 750 mg 
and 500 mg dosing regimens.93
Regulatory affairs
Levofloxacin is approved for use in the US, Canada, and 
worldwide in the treatment of CAP, ABS, complicated UTI, 
and AP.
Conclusion and comments
The respiratory fluoroquinolones are considered to be a sub-
stantial component of the anti-infective armamentarium for the 
treatment of bacterial respiratory infections. Levofloxacin is 
active against most of the respiratory pathogens and has a good 
clinical success rate. Its favorable pharmacodynamics, safety, 
efficacy profile, and tolerability, and also its in vitro activity 
against the common respiratory pathogens, places levofloxa-
cin among first-line agents for the treatment of community-
acquired respiratory tract infections such as CAP.
The Infectious Diseases Society of America/American 
Thoracic Society guidelines recommend that a respiratory 
fluoroquinolone (eg, levofloxacin 750 mg) or a β-lactam 
plus a macrolide be used for the treatment of CAP. The use 
of fluoroquinolones is a reasonable therapeutic choice for 
the treatment of respiratory infections caused by penicillin-
susceptible S. pneumoniae, penicillin-resistant S.   pneumoniae, 
Legionella pneumophilia, H. influenzae, M. pneumoniae, 
and C. pneumoniae.   Levofloxacin combination therapy with 
antipseudomonal β-lactam (or aminoglycoside) should be 
considered if P .   aeruginosa is likely to be a causative patho-
gen of the respiratory infection. S. pneumoniae resistance 
to antibacterial drugs has been a major problem in the US 
and worldwide for more than a decade. Although there are 
reports of the emergence of resistance to some fluoroquino-
lones among S. pneumoniae, the incidence of levofloxacin-
resistant organisms has remained steady at ,1% worldwide. 
In general, levofloxacin shows good in vitro activity against 
clinically relevant Gram-positive, Gram-negative, and atypi-
cal organisms that cause respiratory infections. Levofloxacin 
is active against penicillin-susceptible and -resistant strains 
of S. pneumoniae, the Gram-negative species E. cloacae 
and P . mirabilis, and the atypical organisms C. pneumoniae, 
L. pneumophila, and M. pneumoniae (MIC90 of #2 mg/L). 
Levofloxacin is highly active against the Gram-negative species 
H. influenzae, H. parainfluenzae, and M. catarrhalis (MIC90 
of #0.06 mg/L), including β-lactamase-positive strains of H. 
influenzae and M. catarrhalis. Because the activity of levo-
floxacin is concentration-dependent, the most common predic-
tor of microbiological and clinical efficacy is the AUC:MIC 
ratio. A ratio of .30 was used in some studies to predict in 
vivo activity, particularly against S. pneumoniae. A higher ratio 
(.100) is suggested as being predictive of a bactericidal effect, 
and thus reducing the potential of first-step mutations. Avail-
ability of pneumococcal vaccine is decreasing the incidence 
of pneumococcal infections and decreasing the incidence of 
infections caused by resistant S. pneumoniae.
In the last 5 years, the rate of resistance of S. pneumoniae 
to amoxicillin/clavulanic acid, azithro  mycin, and tetracycline 
appears to have increased, but the levofloxacin resistance rate 
of S. pneumoniae remains #1% worldwide.94   High-dose, 
short-term therapy (levofloxacin 750 mg once daily for 5 days) 
is the standard dosing regimen for levofloxacin in the treat-
ment of CAP worldwide. Increased availability of pneumo-
coccal vaccination programs may decrease the incidence of 
S. pneumoniae as a cause of CAP in adults over time. Other 
problematic infections with multidrug-resistant organisms will 
become the main focus of research in the next 5 years.
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